Acorda Therapeutics' GGF2 shows positive post stroke recovery data in study

Acorda Therapeutics announced data from studies showing that Glial Growth Factor 2 can enhance recovery of sensorimotor function in a preclinical model of stroke. The studies expand on an existing body of preclinical work examining GGF2 in stroke, and specifically explored various doses and frequency of administration to assess optimal treatment regimens. The study showed significant improvements in sensorimotor recovery with GGF2 that were related to dose and frequency of treatment. GGF2 is the leading development candidate from the Company’s neuregulin program.